Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 83 publications
Ferrous Iron Accumulation Is a Hallmark and Therapeutic Vulnerability of Therapy-Induced Senescence.
Ferrous Iron Accumulation Is a Hallmark and Therapeutic Vulnerability of Therapy-Induced Senescence.
Journal: bioRxiv : the preprint server for biology
Published: June 04, 2026
Beyond amplification: precision approaches to targeting HER2.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 01, 2026
Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 09, 2025
Investigating Real-World Evidence and Reported Survival Outcomes of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer.
Journal: Oncology and therapy
Published: September 12, 2025
Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-Mutant Metastatic Breast Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 13, 2025
Spontaneous upregulation of stemness and 3D spheroid formation of single cancer cells induced by scaffold-free polypeptide polyelectrolyte multilayer coating.
Journal: Biomaterials
Published: July 08, 2025
Etirinotecan Pegol (NKTR-102) in Patients With Active Brain Metastases From Lung or Breast Cancer.
Journal: Cancer reports (Hoboken, N.J.)
Published: May 23, 2024
Impact of the Breast Cancer Index for Extended Endocrine Decision-Making: First Results of the Prospective BCI Registry Study.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: July 06, 2023
Corrigendum to "Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis": [Annals of Oncology 33 (2022) 321-329].
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: December 23, 2022
Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancer.
Journal: Therapeutic advances in medical oncology
Published: December 21, 2022
Epidemiology, clinical outcomes, and unmet needs of patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases: A systematic literature review.
Journal: Cancer treatment reviews
Published: December 20, 2022
Last Updated: 09/26/2026